Biovator and BASF sign technology development agreement

The Sweden-based biotech company Biovator and the global chemical industry leader BASF have signed a collaboration agreement for final development of In Vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

“Allergic reactions to compounds are a serious risk in new products that needs to be discovered in the early stages of product development. This collaboration has the potential to open new dimensions in early industrial research that involves testing. The future test product can become an important factor when setting new industry standards,” says Biovator CEO, Stan Mikulowski. To meet the significant market and regulatory need for In Vitro tests in the pharmaceutical sector, Biovator signed an agreement to cooperate with AstraZeneca R&D in 2007, which was an extension of earlier collaboration.